🇺🇸 FDA
Patent

US 12173079

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

granted A61KA61K2039/505A61K47/6807

Quick answer

US patent 12173079 (Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide) held by Dyne Therapeutics, Inc. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889